Immunic, Inc. (IMUX) – What Are Researchers Thinking About This Stock?

Immunic, Inc. (NASDAQ:IMUX) has been given an average recommendation of “Buy” by the twelve brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $35.43.

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Immunic in a report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Roth Capital reiterated a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th.

Immunic Stock Performance

Immunic stock opened at $7.10 on Friday. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43. The stock’s 50 day simple moving average is $12.04 and its two-hundred day simple moving average is $12.66.

Immunic (NASDAQ:IMUX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, equities research analysts expect that Immunic will post -3.71 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. acquired a new position in Immunic in the 1st quarter worth about $27,000. ADAR1 Capital Management LLC acquired a new stake in Immunic in the first quarter valued at approximately $33,000. Seven Fleet Capital Management LP acquired a new stake in Immunic in the fourth quarter valued at approximately $83,000. Bank of America Corp DE increased its position in shares of Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after buying an additional 143,689 shares in the last quarter. Finally, Connective Capital Management LLC purchased a new stake in shares of Immunic in the fourth quarter valued at approximately $161,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.